ivabradine has been researched along with Chronic Kidney Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ameri, P; Brunetti, ND; Canepa, M; Castagno, D; Correale, M; De Ferrari, GM; De Marzo, V; Porto, I; Tricarico, L; Zoccai, GB | 1 |
| Banerjee, D; Wang, AY | 1 |
1 review(s) available for ivabradine and Chronic Kidney Diseases
| Article | Year |
|---|---|
Efficacy of new medical therapies in patients with heart failure, reduced ejection fraction, and chronic kidney disease already receiving neurohormonal inhibitors: a network meta-analysis.
Topics: Clinical Trials, Phase III as Topic; Heart Failure, Systolic; Humans; Ivabradine; Network Meta-Analysis; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Stroke Volume; Ventricular Dysfunction, Left | 2022 |
1 other study(ies) available for ivabradine and Chronic Kidney Diseases
| Article | Year |
|---|---|
Personalizing heart failure management in chronic kidney disease patients.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Creatinine; Diuretics; Glucose; Heart Failure; Humans; Ivabradine; Mineralocorticoid Receptor Antagonists; Neprilysin; Receptors, Angiotensin; Renal Dialysis; Renal Insufficiency, Chronic; Sodium; Stroke Volume | 2022 |